Cited by 2,003Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia ResearchPlatelet Disorders and Treatments

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

Open access

Klampfl, Thorsten, Gisslinger, Heinz, Harutyunyan, Ashot S., Nivarthi, Harini, Rumi, Elisa, Milosevic, Jelena D., Them, Nicole C.C., Berg, Tiina, Gisslinger, Bettina, Pietra, Daniela, Chen, Doris, Vladimer, Gregory I., Bagienski, Klaudia, Milanesi, Chiara, Casetti, Ilaria Carola, Sant'Antonio, Emanuela, Ferretti, Virginia, Elena, Chiara, Schischlik, Fiorella, Cleary, Ciara, Six, Melanie, Schalling, Martin, Schönegger, Andreas, Bock, Christoph, Malcovati, Luca, Pascutto, Cristiana, Superti-Furga, Giulio, Cazzola, Mario, Kralovics, Robert·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1311347

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL). So far, no specific molecular marker has been identified in the remaining 30 to 45% of patients. METHODS: We performed whole-exome sequencing to identify somatically acquired mutations in six patients who had primary myelofibrosis without mutations in JAK2 or MPL. Resequencing of CALR, encoding calreticulin, was then performed in cohorts of patients with myeloid neoplasms. RESULTS: Somatic insertions or deletions in exon 9 of CALR were detected in all patients who underwent whole-exome sequencing. Resequencing in 1107 samples from patients with myeloproliferative neoplasms showed that CALR mutations were absent in polycythemia vera. In essential thrombocythemia and primary myelofibrosis, CALR mutations and JAK2 and MPL mutations were mutually exclusive. Among patients with essential thrombocythemia or primary myelofibrosis with nonmutated JAK2 or MPL, CALR mutations were detected in 67% of those with essential thrombocythemia and 88% of those with primary myelofibrosis. A total of 36 types of insertions or deletions were identified that all cause a frameshift to the same alternative reading frame and generate a novel C-terminal peptide in the mutant calreticulin. Overexpression of the most frequent CALR deletion caused cytokine-independent growth in vitro owing to the activation of signal transducer and activator of transcription 5 (STAT5) by means of an unknown mechanism. Patients with mutated CALR had a lower risk of thrombosis and longer overall survival than patients with mutated JAK2. CONCLUSIONS: Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients was more indolent than that in patients with the JAK2 V617F mutation. (Funded by the MPN Research Foundation and Associazione Italiana per la Ricerca sul Cancro.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1311347

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Self-citation
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E. P., Ebert, B. L., Gozo, M. C., Cuker, A. C., Wernig, G., Moore, S. A., Galinsky, I. A., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,445
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M., Beer, P., Stratton, M. R., Futreal, P., Erber, W., McMullin, M., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,346
The Analysis of Failure Times in the Presence of Competing Risks
Prentice, R. L., Kalbfleisch, J. D., Peterson, A. V., Flournoy, N., Farewell, V. T., & Breslow, N. E. (1978) · Biometrics · doi:10.2307/2530374 · Cited by 1,266
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E. M., Caramella, M., Maffioli, M., et al. (2009) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 997
Self-citation
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A. D., Pereira, A., Finke, C. M., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 793
Self-citation

Flagged first, then by citations

Show all 32 references

Sorted by citations

Items 201–300 of 1,001

Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.
Agarwal, A. M., Morrone, K. A., Bartenstein, M., Zhao, Z. J., Verma, A. K., & Goel, S. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2306-9759.2016.02.03 · Cited by 77
The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms
Holmström, M. O., Riley, C. H., Svane, I. M., Hasselbalch, H. C., & Andersen, M. H. (2016) · Leukemia · doi:10.1038/leu.2016.233 · Cited by 74
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms
Buduo, C. A. D., Abbonante, V., Marty, C., Moccia, F. D., Rumi, E., Pietra, D., Soprano, P. M., Lim, D., Cattaneo, D., Iurlo, A., et al. (2019) · Blood · doi:10.1182/blood.2019001103 · Cited by 74
Self-citation
Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface
Masubuchi, N., Araki, M., Yang, Y., Hayashi, E., Imai, M., Edahiro, Y., Hironaka, Y., Mizukami, Y., Kihara, Y., Takei, H., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0564-z · Cited by 73
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations
Jeromin, S., Haferlach, T., Weißmann, S., Meggendorfer, M., Eder, C., Nadarajah, N., Alpermann, T., Kohlmann, A., Kern, W., Haferlach, C., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.119032 · Cited by 75
The importance of calcium in the regulation of megakaryocyte function
Buduo, C. A. D., Moccia, F. D., Battiston, M., Marco, L. D., Mazzucato, M., Moratti, R., Tanzi, F., & Balduini, A. (2014) · Haematologica · doi:10.3324/haematol.2013.096859 · Cited by 73
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis
Rumi, E., Harutyunyan, A. S., Pietra, D., Feenstra, J. D. M., Casetti, I. C., Bellini, M., Them, N. C. C., Cavalloni, C., Ferretti, V. V., Milanesi, C., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550434 · Cited by 72
Self-citation
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)
Kreher, S., Ochsenreither, S., Trappe, R. U., Pabinger, I., Bergmann, F., Petrides, P. E., Koschmieder, S., Matzdorff, A. C., Tiede, A., Grießhammer, M., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2224-8 · Cited by 72
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
Venton, G., Courtier, F., Charbonnier, A., D’Incan, E., Saillard, C., Mohty, B., Mozziconacci, J., Birnbaum, D., Murati, A., Vey, N., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24973 · Cited by 77
Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease
How, J., Zhou, A. W., & Oh, S. T. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716680333 · Cited by 73
Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms
Jones, A. V., Ward, D., Lyon, M., Leung, W. C. Y., Callaway, A., Chase, A., Dent, C. L., White, H., Drexler, H. G., Nangalia, J., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.11.019 · Cited by 71
Chronic Myelogenous Leukemia, Version 1.2015
O’Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., Curtin, P. T., DeAngelo, D. J., Deininger, M. W., Devine, S. M., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0159 · Cited by 70
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Mesa, R. A., Jamieson, C. H. M., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., Gotlib, J. R., Gundabolu, K., Hobbs, G. S., Klisovic, R. B., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0169 · Cited by 71
JAK inhibitors and COVID-19
Levy, G., Guglielmelli, P., Langmuir, P. B., & Constantinescu, S. N. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002838 · Cited by 70
Genomic landscape of megakaryopoiesis and platelet function defects
Bianchi, E., Norfo, R., Pennucci, V., Zini, R., & Manfredini, R. (2016) · Blood · doi:10.1182/blood-2015-07-607952 · Cited by 70
Single-cell analysis based dissection of clonality in myelofibrosis
Mylonas, E., Yoshida, K., Frick, M., Hoyer, K., Christen, F., Kaeda, J., Obenaus, M., Noerenberg, D., Hennch, C., Chan, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13892-x · Cited by 72
Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden
Hultcrantz, M. L., Landtblom, A. R., Andréasson, B., Samuelsson, J., Dickman, P. W., Kristinsson, S. Y., Björkholm, M., & Andersson, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13019 · Cited by 69
Primary thrombocytosis in children
Kucine, N., Chastain, K. M., Mahler, M., & Bussel, J. B. (2014) · Haematologica · doi:10.3324/haematol.2013.092684 · Cited by 69
Targeting novel signaling pathways for resistant acute myeloid leukemia
Sakamoto, K. M., Grant, S., Saleiro, D., Crispino, J. D., Hijiya, N., Giles, F. J., Platanias, L. C., & Eklund, E. A. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.11.017 · Cited by 69
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Ianotto, J., Chauveau, A., Boyer‐Perrard, F., Gyan, E., Laribi, K., Cony‐Makhoul, P., Demory, J., Renzis, B. D., Dosquet, C., Rey, J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.181297 · Cited by 74
Genomics of Myeloproliferative Neoplasms
Zoi, K., & Cross, N. C. P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7968 · Cited by 73
Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study
Poisson, J., Plessier, A., Kiladjian, J., Turón, F., Cassinat, B., Andreoli, A., de Raucourt, E., Goria, O., Zekrini, K., Bureau, C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.021 · Cited by 68
Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
Andersen, M., Sajid, Z., Pedersen, R. K., Gudmand‐Hoeyer, J., Ellervik, C., Skov, V., Kjær, L., Pallisgaard, N., Kruse, T. A., Thomassen, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183620 · Cited by 68
Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells
Wang, X., Hu, C. S., Petersen, B. E., Qiu, J., Ye, F., Houldsworth, J., Eng, K. H., Huang, F., & Hoffman, R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022012 · Cited by 69
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms
Yue, L., Sharma, V., Horvat, N. P., Akuffo, A. A., Beatty, M. S., Murdun, C., Colin, C., Billington, J. M. R., Goodheart, W. E., Sahakian, E., et al. (2020) · Blood · doi:10.1182/blood.2019895326 · Cited by 67
WHO ‐histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes
Álvarez‐Larrán, A., Ancochea, Á., Garcia, M., Climent, F., García‐Pallarols, F., Angona, A., Senín, A., Barranco, C., Martinez-Aviles, L. M., Serrano, S., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12990 · Cited by 67
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations
Assaf, C. A., Obbergh, F. V., Billiet, J., Lierman, E., Devos, T., Graux, C., Hervent, A.-S., Emmerechts, J., Tousseyn, T., Paepe, P. D., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.118299 · Cited by 67
Biology and therapeutic targeting of molecular mechanisms in MPNs
How, J., Garcia, J. S., & Mullally, A. (2022) · Blood · doi:10.1182/blood.2022017416 · Cited by 75
MEGAKARYOCYTE CONTRIBUTION TO BONE MARROW FIBROSIS: MANY ARROWS IN THE QUIVER
Malara, A., Abbonante, V., Zingariello, M., Migliaccio, A. R., & Balduini, A. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.068 · Cited by 72
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
Valent, P., Kern, W., Hoermann, G., Feenstra, J. D. M., Sotlar, K., Pfeilstöcker, M., Germing, U., Sperr, W. R., Reiter, A., Wolf, D. G. F., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030789 · Cited by 68
Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis
Song, M.-K., Park, B.-B., & Uhm, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030898 · Cited by 70
Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes
Nagata, Y., Narumi, S., Guan, Y., Przychodzen, B. P., Hirsch, C. M., Makishima, H., Shima, H., Aly, M. M., Pastor, V. M. L., Kuzmanovic, T., et al. (2018) · Blood · doi:10.1182/blood-2017-05-787390 · Cited by 65
Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation
Araki, M., Yang, Y., Imai, M., Mizukami, Y., Kihara, Y., Sunami, Y., Masubuchi, N., Edahiro, Y., Hironaka, Y., Osaga, S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0181-2 · Cited by 64
Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
Panagiota, V., Thol, F. R., Markus, B., Fehse, B., Alchalby, H., Badbaran, A., Lehmann, U., Koenecke, C., Shahswar, R., Chaturvedi, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.66 · Cited by 64
JAK 2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort
McGaffin, G., Harper, K., Stirling, D., & McLintock, L. A. (2014) · British Journal of Haematology · doi:10.1111/bjh.12969 · Cited by 64
Calreticulin, a therapeutic target?
Eggleton, P., Bremer, E., Dudek, E., & Michalak, M. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1164695 · Cited by 64
Germline RBBP6 mutations in familial myeloproliferative neoplasms
Harutyunyan, A. S., Giambruno, R., Krendl, C., Stukalov, A., Klampfl, T., Berg, T., Chen, D., Feenstra, J. D. M., Jäger, R., Gisslinger, B., et al. (2015) · Blood · doi:10.1182/blood-2015-09-668673 · Cited by 67
Self-citation
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
Czech, J., Cordua, S., Weinbergerová, B., Baumeister, J., Crepcia, A., Han, L., Maié, T., Costa, I. G., Denecke, B., Maurer, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0295-6 · Cited by 64
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
Grauslund, J. H., Holmström, M. O., Jørgensen, N. G. D., Klausen, U., Weis-Banke, S. E., Fassi, D. E., Schöllkopf, C., Clausen, M. B., Gjerdrum, L. M. R., Breinholt, M. F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637420 · Cited by 64
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
Springuel, L., Renauld, J., & Knoops, L. (2015) · Haematologica · doi:10.3324/haematol.2015.132142 · Cited by 64
The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis
Kramann, R., & Schneider, R. K. (2018) · Blood · doi:10.1182/blood-2018-02-834820 · Cited by 62
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis
Desterke, C., Martinaud, C., Ruzehaji, N., & Bousse‐Kerdilès, M. L. (2015) · Mediators of Inflammation · doi:10.1155/2015/415024 · Cited by 67
A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation
Kollmann, K., Warsch, W., Arias, C. G., Nice, F. L., Avezov, E., Milburn, J. V., Li, J., Dimitropoulou, D., Biddie, S. C., Wang, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.280 · Cited by 62
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
Lussana, F., Carobbio, A., Salmoiraghi, S., Guglielmelli, P., Vannucchi, A. M., Bottazzi, B., Leone, R., Mantovani, A., Barbui, T., & Rambaldi, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0425-z · Cited by 62
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria
Rumi, E., the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators, Boveri, E., Bellini, M., Pietra, D., Ferretti, V. V., Sant’Antonio, E., Cavalloni, C., Casetti, I. C., Roncoroni, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21594 · Cited by 62
Self-citation
The Molecular Genetics of Myeloproliferative NeoplasmsPreprint
Marneth, A. E., & Mullally, A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034876 · Cited by 65
Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms
Arachchillage, D. J., & Laffan, M. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1693477 · Cited by 61
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management
Garmezy, B., Schaefer, J. K., Mercer, J., & Talpaz, M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100691 · Cited by 62
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
Hoermann, G., Greiner, G., & Valent, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/869242 · Cited by 61
Hedgehog signaling in cancer stem cells: a focus on hematological cancers
Campbell, V. L., & Copland, M. (2015) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s58613 · Cited by 62
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
Togasaki, E., Takeda, J., Yoshida, K., Shiozawa, Y., Takeuchi, M., Oshima, M., Saraya, A., Iwama, A., Yokote, K., Sakaida, E., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.36 · Cited by 61
Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants
Masselli, E., Pozzi, G., Gobbi, G., Merighi, S., Gessi, S., Vitale, M., & Carubbi, C. (2020) · Cells · doi:10.3390/cells9092136 · Cited by 63
Calreticulin: Endoplasmic reticulum Ca 2+ gatekeeper
Michalak, M. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17839 · Cited by 60
High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms
Enblom‐Larsson, A., Lindskog, E., Hasselbalch, H. C., Hersby, D. S., Bak, M., Tetu, J., Girodon, F., & Andréasson, B. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.03.009 · Cited by 60
The role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2014) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 63
In utero origin of myelofibrosis presenting in adult monozygotic twins
Sousos, N., Leathlobhair, M. N., Karali, C. S., Louka, E., Bienz, N., Royston, D. J., Clark, S., Hamblin, A. D., Howard, K., Mathews, V., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01793-4 · Cited by 60
Targeting the CALR interactome in myeloproliferative neoplasms
Pronier, E., Cifani, P., Merlinsky, T. R., Berman, K. B., Somasundara, A. V. H., Rampal, R. K., LaCava, J., Wei, K. E., Pastore, F., Mååg, J. L. V., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122703 · Cited by 61
EDA fibronectin–TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis
Malara, A., Gruppi, C., Abbonante, V., Cattaneo, D., Marco, L. D., Massa, M., Iurlo, A., Gianelli, U., Balduini, C. L., Tira, M. E., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181074 · Cited by 63
BMSCs and hematopoiesis
García‐García, A., de Castillejo, C. L. F., & Méndez‐Ferrer, S. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.06.020 · Cited by 61
JAK Inhibitor in CALR-Mutant Myelofibrosis
Passamonti, F., Caramazza, D., & Maffioli, M. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1400499 · Cited by 60
Order Matters: The Order of Somatic Mutations Influences Cancer EvolutionPreprint
Kent, D. G., & Green, A. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027060 · Cited by 61
Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis
Chi, J., Nicolaou, K. A., Nicolaidou, V., Koumas, L., Mitsidou, A., Pierides, C., Manoloukos, M., Barbouti, K., Melanthiou, F., Prokopiou, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.382 · Cited by 58
Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis
Martinaud, C., Desterke, C., Konopacki, J., Pieri, L., Torossian, F., Golub, R., Schmutz, S., Anginot, A., Guerton, B., Rochet, N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3696 · Cited by 58
CALR mutations and a new diagnostic algorithm for MPN
Tefferi, A., & Pardanani, A. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.16 · Cited by 58
Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology
Sheikine, Y., Kuo, F. C., & Lindeman, N. I. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7539 · Cited by 58
The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice
Kuo, F. C., Mar, B. G., Lindsley, R. C., & Lindeman, N. I. (2017) · Blood · doi:10.1182/blood-2017-03-734533 · Cited by 58
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants
Salati, S., Genovese, E., Carretta, C., Zini, R., Bartalucci, N., Prudente, Z., Pennucci, V., Ruberti, S., Rossi, C., Rontauroli, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46843-z · Cited by 59
Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms
Mosca, M., Hermange, G., Tisserand, A., Noble, R., Marzac, C., Marty, C., Le Sueur, C., Campario, H., Vertenoeil, G., El-Khoury, M., et al. (2021) · Blood · doi:10.1182/blood.2021010986 · Cited by 57
Somatic mutations of calreticulin in myeloproliferative neoplasms
Imai, M., Araki, M., & Komatsu, N. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2246-9 · Cited by 56
The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication
Marcellino, B. K., Verstovšek, S., & Mascarenhas, J. O. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.008 · Cited by 57
Clonal hematopoiesis and hematological malignancy
Dunn, W. G., McLoughlin, M. A., & Vassiliou, G. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180065 · Cited by 63
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b
Them, N. C. C., Bagienski, K., Berg, T., Gisslinger, B., Schalling, M., Chen, D., Buxhofer‐Ausch, V., Thaler, J., Schloegl, E., Gastl, G. A., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23928 · Cited by 56
Self-citation
Mpl Traffics to the Cell Surface Through Conventional and Unconventional Routes
Cleyrat, C., Darehshouri, A., Steinkamp, M. P., Vilaine, M., Boassa, D., Ellisman, M. H., Hermouet, S., & Wilson, B. S. (2014) · Traffic · doi:10.1111/tra.12185 · Cited by 56
Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Rufino‐Palomares, E. E., Pérez‐Jiménez, A., Reyes‐Zurita, F. J., Garcı́a-Salguero, L., Mokhtari, K., Herrera-Merchan, A., Medina, P. P., Peragón, J., & Lupiáñez, J. A. (2015) · Current Organic Chemistry · doi:10.2174/1385272819666150119225952 · Cited by 56
Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity
Mair, B., Konopka, T., Kerzendorfer, C., Sleiman, K., Šalic, Š., Serra, V., Muellner, M. K., Theodorou, V., & Nijman, S. M. B. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006279 · Cited by 59
Impact of molecular residual disease post allografting in myelofibrosis patients
Wolschke, C., Badbaran, A., Zabelina, T., Christopeit, M., Ayuk, F. A., Triviai, I., Zander, A., Alchalby, H., Bacher, U., Fehse, B., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.157 · Cited by 56
Myeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Hematology · doi:10.1182/asheducation-2017.1.470 · Cited by 58
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep
Accurso, V., Santoro, M., Mancuso, S., Napolitano, M., Carlisi, M., Mattana, M., Russo, C., Stefano, A. D., Sirocchi, D., & Siragusa, S. M. (2020) · Clinical Medicine Insights Blood Disorders · doi:10.1177/2634853520978210 · Cited by 56
Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis
Tsutsumi, N., Masoumi, Z. T., James, S. C., Tucker, J. A., Winkelmann, H., Grey, W. E., Picton, L. K., Moss, L., Wilson, S. C., Caveney, N. A., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.037 · Cited by 55
Smoking as a contributing factor for development of polycythemia vera and related neoplasms
Hasselbalch, H. C. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.09.002 · Cited by 55
Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis
Broséus, J., Lippert, É., Harutyunyan, A. S., Jeromin, S., Zipperer, E., Florensa, L., Feenstra, J. D. M., Haferlach, T., Germing, U., Luño, E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.49 · Cited by 58
Self-citation
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
Elala, Y. C., Lasho, T. L., Gangat, N., Finke, C. M., Barraco, D., Haider, M., Hussein, A. K. A., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24338 · Cited by 55
The C-Terminal Acidic Region of Calreticulin Mediates Phosphatidylserine Binding and Apoptotic Cell Phagocytosis
Wijeyesakere, S. J., Bedi, S., Huynh, D. A. H., & Raghavan, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502122 · Cited by 57
Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions
Shammo, J. M., & Stein, B. L. (2016) · Hematology · doi:10.1182/asheducation-2016.1.552 · Cited by 57
Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis
Plo, I., Bellanné‐Chantelot, C., Mosca, M., Mazzi, S., Marty, C., & Vainchenker, W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00234 · Cited by 62
Ca2+ Signalling in Endothelial Progenitor Cells: Friend or Foe?
Moccia, F. D., & Guerra, G. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25126 · Cited by 54
Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia
Harrison, C. N., Butt, N. M., Campbell, P. J., Conneally, E., Drummond, M. W., Green, A. R., Murrin, R. J. A., Radia, D. H., Mead, A. J., Reilly, J. T., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12986 · Cited by 54
Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms
McClure, R. F., Ewalt, M. D., Crow, J., Temple‐Smolkin, R., Pullambhatla, M., Sargent, R. L., & Kim, A. S. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.07.002 · Cited by 54
MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
Grabek, J., Straube, J., Bywater, M. J., & Lane, S. (2020) · Cells · doi:10.3390/cells9081901 · Cited by 60
Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia
Chen, C., Gau, J., Chou, H.-J., You, J., Huang, C., Chen, Y. Y., Lung, J., Chou, Y. S., Leu, Y. W., Lu, C., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2151-8 · Cited by 53
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis
Dunbar, A. J., Kim, D., Lü, M., Farina, M., Bowman, R. L., Yang, J. L., Park, Y. C., Karzai, A., Xiao, W., Zaroogian, Z., et al. (2023) · Blood · doi:10.1182/blood.2022015418 · Cited by 57
Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells
Dragoni, S., Reforgiato, M., Zuccolo, E., Poletto, V., Lodola, F., Ruffinatti, F. A., Bonetti, E., Guerra, G., Barosi, G., Rosti, V., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.09.002 · Cited by 53
JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms
Shirane, S., Araki, M., Morishita, S., Edahiro, Y., Takei, H., Yoo, Y., Choi, M., Sunami, Y., Hironaka, Y., Noguchi, M., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.115113 · Cited by 53
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
Heaton, W. L., Senina, A. V., Pomicter, A. D., Salama, M. E., Clair, P. M., Yan, D., Bell, R. N., Gililland, J. M., Prchal, J. T., O’Hare, T., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0131-z · Cited by 56
Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice
Hofmann, I., Geer, M. J., Vögtle, T., Crispin, A., Campagna, D. R., Barr, A., Calicchio, M. L., Heising, S., van Geffen, J. P., Kuijpers, M. J. E., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802769 · Cited by 53
The role of the extracellular matrix in primary myelofibrosis
Leiva, O., Ng, S. K., Chitalia, S. V., Balduini, A., Matsuura, S., & Ravid, K. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.6 · Cited by 55
Heterogeneity in myeloproliferative neoplasms: Causes and consequences
O’Sullivan, J., & Mead, A. J. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.11.007 · Cited by 58
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations
Gangat, N., & Tefferi, A. (2020) · American Journal of Hematology · doi:10.1002/ajh.26067 · Cited by 52
Overview of Myeloproliferative Neoplasms
Tremblay, D. A., Yacoub, A., & Hoffman, R. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.12.001 · Cited by 52
Calreticulin mutations in Chinese with primary myelofibrosis
Li, B., Xu, J., Wang, J., Gale, R. P., Xu, Z., Cui, Y., Yang, L., Xing, R., Ai, X., Qin, T., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.109249 · Cited by 51

Authors: Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G. I., Bagienski, K., Milanesi, C., Casetti, I. C., Sant'Antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schönegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M., & Kralovics, R.
Affiliations: Austrian Academy of Sciences (AT)
Medical University of Vienna (AT)
Policlinico San Matteo Fondazione (IT)
University of Pavia (IT)
ORCID: Klampfl, Thorsten
Gisslinger, Heinz
Harutyunyan, Ashot S.
Nivarthi, Harini
Rumi, Elisa
Pietra, Daniela
Chen, Doris
Vladimer, Gregory I.
Milanesi, Chiara
Casetti, Ilaria Carola
Ferretti, Virginia
Elena, Chiara
Schischlik, Fiorella
Schalling, Martin
Bock, Christoph
Malcovati, Luca
Cazzola, Mario
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-12-19
Volume: 369
Issue: 25
Pages: 2379-2390
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1311347
OpenAlex: W2157694607
Cited by: 2,003
References: 32
Citations by year: 2026: 80 · 2025: 63 · 2024: 81 · 2023: 117 · 2022: 122 · 2021: 173 · 2020: 144 · 2019: 146 · 2018: 153 · 2017: 200 · 2016: 247 · 2015: 243 · 2014: 222 · 2013: 7
FWCI: 118.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords: calreticulin, CALR mutation, myeloproliferative neoplasms, essential thrombocythemia, primary myelofibrosis, JAK2 V617F mutation, MPL mutation, somatic mutations, exon 9 deletion, frameshift mutation, STAT5 activation, thrombosis risk, overall survival
MeSH terms: Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Mutation, Thrombocythemia, Essential, Thrombosis, Proportional Hazards Models, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Receptors, Thrombopoietin, Primary Myelofibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks